The ErbB/HER family of protein-tyrosine kinases and cancer

Pharmacological Research

Volumn 79, Issue , 2014, Pages 34-74

  Roskoski, Robert ^a  

^a Blue Ridge Institute for Medical Research   (United States)

Author keywords

Breast cancer; Colorectal cancer; Monoclonal antibody therapy; Non small cell lung cancer; Small molecule protein kinase inhibitor; Targeted cancer therapy

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYTOTOXIC AGENT; DACTINOMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; HETERODIMER; HOMODIMER; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PANITUMUMAB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG;

BREAST CANCER; CANCER CLASSIFICATION; CANCER THERAPY; CELL NUCLEUS; COLORECTAL CANCER; ENZYME LOCALIZATION; ENZYME STRUCTURE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LIGAND BINDING; LUNG CANCER; MULTIGENE FAMILY; NEOPLASM; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

4-(3-CHLOROANILINO) QUINAZOLINE; 5-FLUOROURACIL (PUBCHEM CID: 3385); ACTIVATION LOOP; ADCC; ADO-TRASTUZUMAB EMTANSINE; ADO-TRASTUZUMAB-DM1; AFATINIB (PUBCHEM CID: 10184653); AL; AMPHIREGULIN; ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; AR; BETACELLULIN; BREAST CANCER; BTC; C-SPINE; CAQ; CATALYTIC SPINE; CDK; CENTRAL NERVOUS SYSTEM; CNS; COLORECTAL CANCER; CRC; CYCLIN-DEPENDENT KINASE; DOCETAXEL (PUBCHEM CID: 148124); DOXORUBICIN (PUBCHEM CID: 31703); EC; EGFR; EPG; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGEN; EPIREGULIN; EPR; ERLOTINIB (PUBCHEM CID: 176870); EXTRACELLULAR; FDA; FISH; FLUORESCENT IN SITU HYBRIDIZATION; GEFITINIB (PUBCHEM CID: 123631); HB-EGF; HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR; JM; JUXTAMEMBRANE; LAPATINIB (PUBCHEM CID: 208908); LE; LIGAND EFFICIENCY; LIPE; LIPOPHILIC EFFICIENCY; MAB; MOLECULAR WEIGHT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY THERAPY; MW; NEUREGULIN; NON-SMALL CELL LUNG CANCER; NRG; NSCLC; OXALIPLATIN (PUBCHEM CID: 5310940); PEMETREXED (PUBCHEM CID: 446556); PHOSPHATASE AND TENSIN HOMOLOG; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C; PI3K; PK; PLC; PROTEIN KINASE; PTEN; R-SPINE; REGORAFENIB (PUBCHEM CID: 11167602); REGULATORY SPINE; SMALL MOLECULE PROTEIN KINASE INHIBITOR; TARGETED CANCER THERAPY; TGFΑ; TM; TRANSFORMING GROWTH FACTOR Α; TRANSMEMBRANE; UNITED STATES FOOD AND DRUG ADMINISTRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGFR;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LIGANDS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84890041471     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.11.002     Document Type: Review

References (305)

1. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
2. S. Cohen The epidermal growth factor (EGF) Cancer 51 1983 1787 1791 (Pubitemid 13093942)
3. G. Carpenter, and S. Cohen Epidermal growth factor J Biol Chem 265 1990 7709 7712 (Pubitemid 20158927)
4. S. Cohen, H. Ushiro, C. Stoscheck, and M. Chinkers A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles J Biol Chem 257 1982 1523 1531 (Pubitemid 12121664)
5. D.M. Thompson, and G.N. Gill The EGF receptor: structure, regulation, and potential role in malignancy Cancer Surv 4 1985 767 788
6. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934 (Pubitemid 35425239)
7. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, I. Friedberg, and A. Osterman Protein tyrosine phosphatases in the human genome Cell 117 2004 699 711 (Pubitemid 38748887)
8. H.M. Wain, E.A. Bruford, R.C. Lovering, M.J. Lush, M.W. Wright, and S. Povey Guidelines for human gene nomenclature Genomics 79 2002 464 470 (Pubitemid 34274283)
9. L.J. Maltais, J.A. Blake, T. Chu, C.M. Lutz, J.T. Eppig, and I. Jackson Rules and guidelines for mouse gene, allele, and mutation nomenclature: a condensed version Genomics 79 2002 471 474 (Pubitemid 34274284)
10. G. Levan, H.J. Hedrich, E.F. Remmers, T. Serikawa, and M.C. Yoshida Standardized rat genetic nomenclature Mamm Genome 6 1995 447 448
11. A.L. Schechter, D.F. Stern, L. Vaidyanathan, S.J. Decker, J.A. Drebin, and M.I. Greene The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 312 1984 513 516 (Pubitemid 15182278)
12. A. Citri, and Y. Yarden EGF-ERBB signalling: towards the systems level Nat Rev Mol Cell Biol 7 2006 505 516 (Pubitemid 44036456)
13. S. Britsch The neuregulin-I/ErbB signaling system in development and disease Adv Anat Embryol Cell Biol 190 2007 1 6
14. V. Rajagopalan, I.H. Zucker, J.A. Jones, M. Carlson, and Y.J. Ma Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction Am J Physiol Heart Circ Physiol 295 2008 H543 H554
15. P.J. Miettinen, J.E. Berger, J. Meneses, Y. Phung, R.A. Pedersen, and Z. Werb Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor Nature 376 1995 337 341
16. D.W. Threadgill, A.A. Dlugosz, L.A. Hansen, T. Tennenbaum, U. Lichti, and D. Yee Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype Science 269 1995 230 234
17. M. Gassmann, F. Casagranda, D. Orioli, H. Simon, C. Lai, and R. Klein Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor Nature 378 1995 390 394
18. K.F. Lee, H. Simon, H. Chen, B. Bates, M.C. Hung, and C. Hauser Requirement for neuregulin receptor erbB2 in neural and cardiac development Nature 378 1995 394 398
19. D. Riethmacher, E. Sonnenberg-Riethmacher, V. Brinkmann, T. Yamaai, G.R. Lewin, and C. Birchmeier Severe neuropathies in mice with targeted mutations in the ErbB3 receptor Nature 389 1997 725 730 (Pubitemid 27458958)
20. A. Ullrich, L. Coussens, J.S. Hayflick, T.J. Dull, A. Gray, and A.W. Tam Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells Nature 309 1984 418 425 (Pubitemid 14102443)
21. K. Elenius, G. Corfas, S. Paul, C.J. Choi, C. Rio, and G.D. Plowman A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester J Biol Chem 272 1997 26761 26768 (Pubitemid 27458905)
22. R. Ghosh, A. Narasanna, S.E. Wang, S. Liu, A. Chakrabarty, and J.M. Balko Trastuzumab has preferential activity against breast cancers driven by ERBB2 homodimers Cancer Res 71 2011 1871 1882
23. F. Shi, S.E. Telesco, Y. Liu, R. Radhakrishnan, and M.A. Lemmon ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation Proc Natl Acad Sci USA 107 2010 7692 7697
24. E. Tzahar, H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, and S. Lavi A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor Mol Cell Biol 16 1996 5276 5287 (Pubitemid 26315047)
25. D. Graus-Porta, R.R. Beerli, J.M. Daly, and N.E. Hynes ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J 16 1997 1647 1655 (Pubitemid 27151960)
26. R. Pinkas-Kramarski, L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, and L. Klapper Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions EMBO J 15 1996 2452 2467 (Pubitemid 26151185)
27. W.J. Gullick The Type 1 growth factor receptors and their ligands considered as a complex system Endocr Relat Cancer 8 2001 75 82 (Pubitemid 32641350)
28. C.P. Blobel ADAMs: key components in EGFR signalling and development Nat Rev Mol Cell Biol 6 2005 32 43 (Pubitemid 40064897)
29. N. Rocks, G. Paulissen, M. El Hour, F. Quesada, C. Crahay, and M. Gueders Emerging roles of ADAM and ADAMTS metalloproteinases in cancer Biochimie 90 2008 369 379 (Pubitemid 351172571)
30. J. Scheller, A. Chalaris, C. Garbers, and S. Rose-John ADAM17: a molecular switch to control inflammation and tissue regeneration Trends Immunol 32 2011 380 387
31. S. Rose-John ADAM17, shedding, TACE as therapeutic targets Pharmacol Res 71 2013 19 22
32. J. Schlessinger Ligand-induced, receptor-mediated dimerization and activation of EGF receptor Cell 110 2002 669 672 (Pubitemid 35283957)
33. M. Aritomi, N. Kunishima, T. Okamoto, R. Kuroki, Y. Ota, and K. Morikawa Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme Nature 401 1999 713 717
34. H. Ogiso, R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, and J.H. Kim Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains Cell 110 2002 775 787 (Pubitemid 35291060)
35. T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, and G.O. Lovrecz Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α Cell 110 2002 763 773 (Pubitemid 35283965)
36. T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, and G.O. Lovrecz The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors Mol Cell 11 2003 495 505 (Pubitemid 36293841)
37. K.M. Ferguson, M.B. Berger, J.M. Mendrola, H.S. Cho, D.J. Leahy, and M.A. Lemmon EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization Mol Cell 11 2003 507 517 (Pubitemid 36297057)
38. A.W. Burgess, H.S. Cho, C. Eigenbrot, K.M. Ferguson, T.P. Garrett, and D.J. Leahy An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors Mol Cell 12 2003 541 552 (Pubitemid 37222478)
39. H.S. Lu, J.J. Chai, M. Li, B.R. Huang, C.H. He, and R.C. Bi Crystal structure of human epidermal growth factor and its dimerization J Biol Chem 276 2001 34913 34917
40. T. Domagala, N. Konstantopoulos, F. Smyth, R.N. Jorissen, L. Fabri, and D. Geleick Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor Growth Factors 18 2000 11 29 (Pubitemid 30303652)
41. H.S. Cho, and D.J. Leahy Structure of the extracellular region of HER3 reveals an interdomain tether Science 297 2002 1330 1333 (Pubitemid 34913167)
42. S. Bouyain, P.A. Longo, S. Li, K.M. Ferguson, and D.J. Leahy The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand Proc Natl Acad Sci USA 102 2005 15024 15029 (Pubitemid 41513328)
43. H.S. Cho, K. Mason, K.X. Ramyar, A.M. Stanley, S.B. Gabelli, and D.W. Denney Jr. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 2003 756 760 (Pubitemid 36227628)
44. P. Liu, T.E. Cleveland 4th, S. Bouyain, P.O. Byrne, P.A. Longo, and D.J. Leahy A single ligand is sufficient to activate EGFR dimers Proc Natl Acad Sci USA 109 2012 1086 1096
45. D. Alvarado, D.E. Klein, and M.A. Lemmon Structural basis for negative cooperativity in growth factor binding to an EGF receptor Cell 142 2010 568 579
46. J.L. Macdonald-Obermann, S. Adak, R. Landgraf, D. Piwnica-Worms, and L.J. Pike Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging J Biol Chem 288 2013 30773 30784
47. M. Huse, and J. Kuriyan The conformational plasticity of protein kinases Cell 109 2002 275 282 (Pubitemid 34606870)
48. S.S. Taylor, M.M. Keshwani, J.M. Steichen, and A.P. Kornev Evolution of the eukaryotic protein kinases as dynamic molecular switches Philos Trans R Soc Lond Biol Sci 367 2012 2517 2528
49. D.R. Knighton, J.H. Zheng, L.F. Ten Eyck, V.A. Ashford, N.H. Xuong, and S.S. Taylor Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 407 414 (Pubitemid 21917165)
50. S.K. Hanks, A.M. Quinn, and T. Hunter The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science 241 1988 42 52
51. P.A. Schwartz, and B.W. Murray Protein kinase biochemistry and drug discovery Bioorg Chem 39 2011 192 210
52. A.P. Kornev, N.M. Haste, S.S. Taylor, and L.F. Eyck Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc Natl Acad Sci USA 103 2006 17783 17788 (Pubitemid 44852237)
53. H.S. Meharena, P. Chang, M.M. Keshwani, K. Oruganty, A.K. Nene, and N. Kannan Deciphering the structural basis of eukaryotic protein kinase regulation PLoS Biol 11 2013 e1001680
54. B. Nolen, S. Taylor, and G. Ghosh Regulation of protein kinases: controlling activity through activation segment conformation Mol Cell 15 2004 661 675 (Pubitemid 39194898)
55. N. Gotoh, A. Tojo, M. Hino, Y. Yazaki, and M. Shibuya A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor Biochem Biophys Res Commun 186 1992 768 774
56. D.A. Tice, J.S. Biscardi, A.L. Nickles, and S.J. Parsons Mechanism of biological synergy between cellular Src and epidermal growth factor receptor Proc Natl Acad Sci USA 96 1999 1415 1420 (Pubitemid 29098465)
57. P.M. Guy, J.V. Platko, L.C. Cantley, R.A. Cerione, and K.L. Carraway 3rd Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity Proc Natl Acad Sci USA 91 1994 8132 8136
58. A. Citri, K.B. Skaria, and Y. Yarden The deaf and the dumb: the biology of ErbB-2 and ErbB-3 Exp Cell Res 284 2003 54 65 (Pubitemid 36342255)
59. J. Boudeau, D. Miranda-Saavedra, G.J. Barton, and D.R. Alessi Emerging roles of pseudokinases Trends Cell Biol 16 2006 443 452 (Pubitemid 44293399)
60. Q. Zhang, E. Park, K. Kani, and R. Landgraf Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling Proc Natl Acad Sci USA 109 2012 13237 13242
61. S.S. Taylor, and A.P. Kornev Protein kinases: evolution of dynamic regulatory proteins Trends Biochem Sci 36 2011 65 77
62. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 9 2009 28 39
63. J.S. Biscardi, M.C. Maa, D.A. Tice, M.E. Cox, T.H. Leu, and S.J. Parsons c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function J Biol Chem 274 1999 8335 8343
64. X. Zhang, J. Gureasko, K. Shen, P.A. Cole, and J. Kuriyan An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125 2006 1137 1149 (Pubitemid 43866200)
65. J.L. Macdonald-Obermann, D. Piwnica-Worms, and L.J. Pike Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging Proc Natl Acad Sci USA 109 2012 137 142
66. M. Red Brewer, S.H. Choi, D. Alvarado, K. Moravcevic, A. Pozzi, and M.A. Lemmon The juxtamembrane region of the EGF receptor functions as an activation domain Mol Cell 34 2009 641 651
67. A. Arkhipov, Y. Shan, R. Das, N.F. Endres, M.P. Eastwood, and D.E. Wemmer Architecture and membrane interactions of the EGF receptor Cell 152 2013 557 569
68. N. Jura, N.F. Endres, K. Engel, S. Deindl, R. Das, and M.H. Lamers Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment Cell 137 2009 1293 1307
69. E.R. Wood, L.M. Shewchuk, B. Ellis, P. Brignola, R.L. Brashear, and T.R. Caferro 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases Proc Natl Acad Sci USA 105 2008 2773 2778 Erratum in: Proc Natl Acad Sci USA 2008;105:6208 (Pubitemid 351723619)
70. E.V. Bocharov, K.S. Mineev, P.E. Volynsky, Y.S. Ermolyuk, E.N. Tkach, and A.G. Sobol Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state J Biol Chem 283 2008 6950 6956
71. K.S. Mineev, E.V. Bocharov, Y.E. Pustovalova, O.V. Bocharova, V.V. Chupin, and A.S. Arseniev Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases J Mol Biol 400 2010 231 243
72. B. Brosig, and D. Langosch The dimerization motif of the glycophorin A transmembrane segment in membranes: importance of glycine residues Protein Sci 7 1998 1052 1056 (Pubitemid 28216547)
73. C. Escher, F. Cymer, and D. Schneider Two GxxxG-like motifs facilitate promiscuous interactions of the human ErbB transmembrane domains J Mol Biol 389 2009 10 16
74. C. Lu, L.Z. Mi, M.J. Grey, J. Zhu, E. Graef, and S. Yokoyama Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor Mol Cell Biol 30 2010 5432 5443
75. N.F. Endres, R. Das, A.W. Smith, A. Arkhipov, E. Kovacs, and Y. Huang Conformational coupling across the plasma membrane in activation of the EGF receptor Cell 152 2013 543 556
76. N.J. Bessman, and M.A. Lemmon Finding the missing links in EGFR Nat Struct Mol Biol 19 2012 1 3
77. I. Chung, R. Akita, R. Vandlen, D. Toomre, J. Schlessinger, and I. Mellman Spatial control of EGF receptor activation by reversible dimerization on living cells Nature 464 2010 783 787
78. L.Z. Mi, C. Lu, Z. Li, N. Nishida, T. Walz, and T.A. Springer Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor Nat Struct Mol Biol 18 2011 984 989
79. J. Kästner, H.H. Loeffler, S.K. Roberts, M.L. Martin-Fernandez, and M.D. Winn Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics J Struct Biol 167 2009 117 128
80. Y. Yarden, and M.X. Sliwkowski Nat Rev Mol Cell Biol 2 2001 127 137
81. Y. Yarden, and G. Pines The ERBB network: at last, cancer therapy meets systems biology Nat Rev Cancer 12 2012 553 563
82. P. Seshacharyulu, M.P. Ponnusamy, D. Haridas, M. Jain, A.K. Ganti, and S.K. Batra Targeting the EGFR signaling pathway in cancer therapy Expert Opin Ther Targets 16 2012 15 31
83. K.J. Wilson, J.L. Gilmore, J. Foley, M.A. Lemmon, and D.J. Riese 2nd Functional selectivity of EGF family peptide growth factors: implications for cancer Pharmacol Ther 122 2009 1 8
84. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 2009 550 562
85. B. Vanhaesebroeck, L. Stephens, and P. Hawkins PI3K signalling: the path to discovery and understanding Nat Rev Mol Cell Biol 13 2012 195 203
86. R. Roskoski Jr. RAF protein-serine/threonine kinases: structure and regulation Biochem Biophys Res Commun 399 2010 313 317
87. R. Roskoski Jr. MEK1/2 dual-specificity protein kinases: structure and regulation Biochem Biophys Res Commun 417 2012 5 10
88. R. Roskoski Jr. ERK1/2 MAP kinases: structure, function, and regulation Pharmacol Res 66 2012 105 143
89. E.J. Lowenstein, R.J. Daly, A.G. Batzer, W. Li, B. Margolis, and R. Lammers The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling Cell 70 1992 431 442
90. W. Li, and H. She The SH2 and SH3 adapter Nck: a two-gene family and a linker between tyrosine kinases and multiple signaling networks Histol Histopathol 15 2000 947 955 (Pubitemid 30488574)
91. Y. Kobashigawa, M. Sakai, M. Naito, M. Yokochi, H. Kumeta, and Y. Makino Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK Nat Struct Mol Biol 14 2007 503 510 (Pubitemid 46871805)
92. P. Tamás, Z. Solti, P. Bauer, A. Illés, S. Sipeki, and A. Bauer Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac J Biol Chem 278 2003 5163 5171 (Pubitemid 36801028)
93. L. Xia, L. Wang, A.S. Chung, S.S. Ivanov, M.Y. Ling, and A.M. Dragoi Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation J Biol Chem 277 2002 30716 33023
94. M. Mazzocco, M. Maffei, A. Egeo, A. Vergano, P. Arrigo, and R. Di Lisi The identification of a novel human homologue of the SH3 binding glutamic acid-rich (SH3BGR) gene establishes a new family of highly conserved small proteins related to thioredoxin superfamily Gene 291 2002 233 239 (Pubitemid 34722393)
95. A.A. Khalil, and P. James Biomarker discovery: a proteomic approach for brain cancer profiling Cancer Sci 98 2007 201 213 (Pubitemid 44941872)
96. J. Downward Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 2003 11 22 (Pubitemid 37328883)
97. B. Tocque, I. Delumeau, F. Parker, F. Maurier, M.C. Multon, and F. Schweighoffer Ras-GTPase activating protein (GAP): a putative effector for Ras Cell Signal 9 1997 153 158 (Pubitemid 27186914)
98. R. Roskoski Jr. Src protein-tyrosine kinase structure and regulation Biochem Biophys Res Commun 324 2004 1155 1164 (Pubitemid 40292143)
99. S. Panjarian, R.E. Iacob, S. Chen, J.R. Engen, and T.E. Smithgall Structure and dynamic regulation of Abl kinases J Biol Chem 288 2013 5443 5450
100. Z.A. Stewart, and J.A. Pietenpol Syk: a new player in the field of breast cancer Breast Cancer Res 3 2001 5 7 (Pubitemid 32223644)
101. G. Kadamur, and E.M. Ross Mammalian phospholipase C Annu Rev Physiol 75 2013 127 154
102. G. Martiny-Baron, and D. Fabbro Classical PKC isoforms in cancer Pharmacol Res 55 2007 477 486 (Pubitemid 46970734)
103. E. Totoń, E. Ignatowicz, K. Skrzeczkowska, and M. Rybczyńska Protein kinase CÉ as a cancer marker and target for anticancer therapy Pharmacol Rep 63 2011 19 29
104. D. Mochly-Rosen, K. Das, and K.V. Grimes Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 11 2012 937 957
105. A. Basu, and U. Sivaprasad Protein kinase CÉ makes the life and death decision Cell Signal 19 2007 1633 1642 (Pubitemid 46935437)
106. E. Krasnitsky, Y. Baumfeld, J. Freedman, N. Sion-Vardy, S. Ariad, and V. Novack PKCη is a novel prognostic marker in non-small cell lung cancer Anticancer Res 32 2012 1507 1513
107. P. López-Ruiz, J. Rodriguez-Ubreva, A.E. Cariaga, M.A. Cortes, and B. Colás SHP-1 in cell-cycle regulation Anticancer Agents Med Chem 11 2011 89 98
108. J. Yang, L. Liu, D. He, X. Song, X. Liang, and Z.J. Zhao Crystal structure of human protein-tyrosine phosphatase SHP-1 J Biol Chem 278 2003 6516 6520 (Pubitemid 36800913)
109. T. Tenev, S.A. Böhmer, R. Kaufmann, S. Frese, T. Bittorf, and T. Beckers Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells Eur J Cell Biol 79 2000 261 271 (Pubitemid 30232571)
110. L. Insabato, I. Amelio, M. Quarto, A. Zannetti, F. Tolino, and G. de Mauro Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors Oncology 77 2009 378 384
111. Y.M. Agazie, and M.J. Hayman Development of an efficient substrate-trapping mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates J Biol Chem 278 2003 13952 13958 (Pubitemid 36799937)
112. X. Zhou, and Y.M. Agazie Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation J Biol Chem 284 2009 12226 12234
113. W.Y. Langdon, J.W. Hartley, S.P. Klinken, S.K. Ruscetti, and H.C. Morse v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas Proc Natl Acad Sci USA 86 1989 1168 1172 (Pubitemid 19061515)
114. K.E. Longva, F.D. Blystad, E. Stang, A.M. Larsen, L.E. Johannessen, and I.H. Madshus Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies J Cell Biol 156 2002 843 854 (Pubitemid 34839867)
115. K. Umebayashi, H. Stenmark, and T. Yoshimori Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation Mol Biol Cell 19 2008 3454 3462
116. K. Haglund, and I. Dikic The role of ubiquitylation in receptor endocytosis and endosomal sorting J Cell Sci 125 2012 265 275
117. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts J Cell Biol 71 1976 159 171
118. A. Sorkin, and C.M. Waters Endocytosis of growth factor receptors Bioessays 15 1993 375 382
119. J. Baulida, M.H. Kraus, M. Alimandi, P.P. Di Fiore, and G. Carpenter All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired J Biol Chem 271 1996 5251 5257 (Pubitemid 26075021)
120. G. Carpenter, and H.J. Liao Trafficking of receptor tyrosine kinases to the nucleus Exp Cell Res 315 2009 1556 1566
121. U. Marti, S.J. Burwen, A. Wells, M.E. Barker, S. Huling, and A.M. Feren Localization of epidermal growth factor receptor in hepatocyte nuclei Hepatology 13 1991 15 20
122. Y.N. Wang, H. Yamaguchi, J.M. Hsu, and M.C. Hung Nuclear trafficking of the epidermal growth factor receptor family membrane proteins Oncogene 29 2010 3997 4006
123. L. Xu, and J. Massagué Nucleocytoplasmic shuttling of signal transducers Nat Rev Mol Cell Biol 5 2004 209 219 (Pubitemid 38325802)
124. A. Hoelz, E.W. Debler, and G. Blobel The structure of the nuclear pore complex Annu Rev Biochem 80 2011 613 643
125. K.H. Chow, R.E. Factor, and K.S. Ullman The nuclear envelope environment and its cancer connections Nat Rev Cancer 12 2012 196 209
126. H.W. Lo, M. Ali-Seyed, Y. Wu, G. Bartholomeusz, S.C. Hsu, and M.C. Hung Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1 J Cell Biochem 98 2006 1570 1583 (Pubitemid 44141861)
127. D.K. Giri, M. Ali-Seyed, L.Y. Li, D.F. Lee, P. Ling, and G. Bartholomeusz Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor Mol Cell Biol 25 2005 11005 11018 (Pubitemid 41747142)
128. D. Xu, A. Farmer, and Y.M. Chook Recognition of nuclear targeting signals by Karyopherin-β proteins Curr Opin Struct Biol 20 2010 782 790
129. S. Kuersten, M. Ohno, and I.W. Mattaj Nucleocytoplasmic transport: Ran, beta and beyond Trends Cell Biol 11 2001 497 503 (Pubitemid 33079143)
130. S.C. Hsu, and M.C. Hung Characterization of a novel tripartite nuclear localization sequence in the EGFR family J Biol Chem 282 2007 10432 10440
131. S.C. Wang, and M.C. Hung Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors Clin Cancer Res 15 2009 6484 6489
132. S.Y. Lin, K. Makino, W. Xia, A. Matin, Y. Wen, and K.Y. Kwong Nuclear localization of EGF receptor and its potential new role as a transcription factor Nat Cell Biol 3 2001 802 808 (Pubitemid 32842685)
133. T.M. Brand, M. Iida, N. Luthar, M.J. Wleklinski, M.M. Starr, and D.L. Wheeler Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3 PLoS One 8 2013 e71518
134. C. Napoli, A. Giordano, A. Casamassimi, F. Pentimalli, L.J. Ignarro, and F. De Nigris Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer Int J Cancer 128 2011 1505 1508
135. S.P. Sardi, J. Murtie, S. Koirala, B.A. Patten, and G. Corfas Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain Cell 127 2006 185 197 (Pubitemid 44466644)
136. I.J. Fox, and H.I. Kornblum Developmental profile of ErbB receptors in murine central nervous system: implications for functional interactions J Neurosci Res 79 2005 584 597 (Pubitemid 40476437)
137. C. Li, M. Iida, E.F. Dunn, A.J. Ghia, and D.L. Wheeler Nuclear EGFR contributes to acquired resistance to cetuximab Oncogene 28 2009 3801 3813
138. T.M. Brand, E.F. Dunn, M. Iida, R.A. Myers, K.T. Kostopoulos, and C. Li Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab Cancer Biol Ther 12 2011 436 446
139. J. Schlessinger, and M.A. Lemmon Nuclear signaling by receptor tyrosine kinases: the first robin of spring Cell 127 2006 45 48 (Pubitemid 44466641)
140. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
141. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
142. R.S. Herbst, J.V. Heymach, and S.M. Lippman Lung cancer N Engl J Med 359 2008 1367 1380
143. L.G. Collins, C. Haines, R. Perkel, and R.E. Enck Lung cancer: diagnosis and management Am Fam Physician 75 2007 56 63 (Pubitemid 46064483)
144. P. Goldstraw, J. Crowley, K. Chansky, D.J. Giroux, P.A. Groome, and R. Rami-Porta The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2 2007 706 714 Erratum in: J Thorac Oncol 2007;2:985 (Pubitemid 47357522)
145. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, and A. Dowlati Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
146. B.A. Chabner, and D.L. Longo Cancer chemotherapy and biotherapy: principles and practice 5th ed. 2011 Lippincott Williams & Wilkins Philadelphia
147. J.C. Soria, A. Mauguen, M. Reck, A.B. Sandler, N. Saijo, and D.H. Johnson Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer Ann Oncol 24 2013 20 30 Erratum in: Ann Oncol 2013;24:1133
148. M. Wang, and M. Thanou Targeting nanoparticles to cancer Pharmacol Res 62 2010 90 99
149. V.D. Cataldo, D.L. Gibbons, R. Pérez-Soler, and A. Quintás-Cardama Treatment of non-small-cell lung cancer with erlotinib or gefitinib N Engl J Med 364 2011 947 955
150. M.H. Cohen, G.A. Williams, R. Sridhara, G. Chen, W.D. McGuinn Jr., and D. Morse United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 2004 1212 1218 (Pubitemid 38365209)
151. R. Bailey, M. Kris, and M. Wolf Gefitinib (Iressa, ZD 1839) monotherapy for pretreated advanced non-small cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone Lung Cancer 41 2003 S71 [abstract O-242]
152. M.H. Cohen, J.R. Johnson, Y.F. Chen, R. Sridhara, and R. Pazdur FDA drug approval summary: erlotinib (Tarceva) tablets Oncologist 10 2005 461 466 (Pubitemid 41266326)
153. H.B. Liu, Y. Wu, T.F. Lv, Y.W. Yao, Y.Y. Xiao, and D.M. Yuan Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis PLoS One 8 2013 e55128
154. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
155. J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
156. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, and I. Sarkaria EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311 (Pubitemid 39209661)
157. E. Massarelli, F.M. Johnson, H.S. Erickson, I.I. Wistuba, and V. Papadimitrakopoulou Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance Lung Cancer 80 2013 235 241
158. W. Pao, and J. Chmielecki Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat Rev Cancer 10 2010 760 774
159. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
160. T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, and J. Tsurutani Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
161. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, and C. Camps Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
162. C.H. Yun, T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, and M. Meyerson Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 2007 217 227 (Pubitemid 46349842)
163. P.F. Cook, and W.W. Cleland Enzyme kinetics and mechanism 2007 Garland Science New York 8
164. M. Red Brewer, C.H. Yun, D. Lai, M.A. Lemmon, M.J. Eck, and W. Pao Mechanism for activation of mutated epidermal growth factor receptors in lung cancer Proc Natl Acad Sci USA 110 2013 E3595 E3604
165. W.H. Ward, P.N. Cook, A.M. Slater, D.H. Davies, G.A. Holdgate, and L.R. Green Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor Biochem Pharmacol 48 1994 659 666
166. D.J. Giard, S.A. Aaronson, G.J. Todaro, P. Arnstein, J.H. Kersey, and H. Dosik In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors J Natl Cancer Inst 51 1973 1417 1423
167. P.F. Cook, M.E. Neville Jr., K.E. Vrana, F.T. Hartl, and R. Roskoski Jr. Adenosine cyclic 3′,5′-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit Biochemistry 21 1982 5794 5799
168. C.V. Parast, B. Mroczkowski, C. Pinko, S. Misialek, G. Khambatta, and K. Appelt Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis Biochemistry 37 1998 16788 16801 (Pubitemid 28543942)
169. A.E. Wakeling, A.J. Barker, D.H. Davies, D.S. Brown, L.R. Green, and S.A. Cartlidge Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines Breast Cancer Res Treat 38 1996 67 73 (Pubitemid 26031067)
170. G.W. Rewcastle, W.A. Denny, A.J. Bridges, H. Zhou, D.R. Cody, and A. McMichael Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl) amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor J Med Chem 38 1995 3482 3487
171. A.J. Barker, K.H. Gibson, W. Grundy, A.A. Godfrey, J.J. Barlow, and M.P. Healy Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg Med Chem Lett 11 2001 1911 1914 (Pubitemid 32675316)
172. J.D. Moyer, E.G. Barbacci, K.K. Iwata, L. Arnold, B. Boman, and A. Cunningham Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 1997 4838 4848 (Pubitemid 27468992)
173. V.A. Pollack, D.M. Savage, D.A. Baker, K.E. Tsaparikos, D.E. Sloan, and J.D. Moyer Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice J Pharmacol Exp Ther 291 1999 739 748 (Pubitemid 29503548)
174. D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, and L.R. Chirieac BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
175. F. Solca, G. Dahl, A. Zoephel, G. Bader, M. Sanderson, and C. Klein Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker J Pharmacol Exp Ther 343 2012 342 350
176. L. Paz-Ares, D. Soulières, I. Melezínek, J. Moecks, L. Keil, and T. Mok Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis J Cell Mol Med 14 2010 51 69
177. L.V. Sequist, B.A. Waltman, D. Dias-Santagata, S. Digumarthy, A.B. Turke, and P. Fidias Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Trans Med 3 2011 75ra26
178. C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, and K.K. Wong The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci USA 105 2008 2070 2075 (Pubitemid 351439466)
179. R. Roskoski Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition Pharmacol Res 68 2013 68 94
180. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, and J.O. Park MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043 (Pubitemid 46799492)
181. R. Roskoski Jr. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders Expert Opin Drug Discov 8 2013 1165 1179
182. M.E. Arcila, J.E. Chaft, K. Nafa, S. Roy-Chowdhuri, C. Lau, and M. Zaidinski Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas Clin Cancer Res 18 2012 4910 4918
183. F. Cappuzzo, L. Bemis, and M. Varella-Garcia HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer N Engl J Med 354 2006 2619 2621 (Pubitemid 43882374)
184. J. De Grève, E. Teugels, C. Geers, L. Decoster, D. Galdermans, and J. De Mey Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu Lung Cancer 76 2012 123 127
185. J.L. Wittliff Steroid-hormone receptors in breast cancer Cancer 53 1984 630 643
186. R. Siegel, C. DeSantis, K. Virgo, K. Stein, A. Mariotto, and T. Smith Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 2012 220 241 Erratum in: CA Cancer J Clin 2012;62:348
187. G. von Minckwitz Docetaxel/anthracycline combinations for breast cancer treatment Expert Opin Pharmacother 8 2007 485 495
188. W. Xia, R.J. Mullin, B.R. Keith, L.H. Liu, H. Ma, and D.W. Rusnak Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 21 2002 6255 6263
189. C.E. Geyer, J. Forster, D. Lindquist, S. Chan, C.G. Romieu, and T. Pienkowski Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743 Erratum in: N Engl J Med 2007;356:1487 (Pubitemid 46021510)
190. R. Riemsma, C.A. Forbes, M.M. Amonkar, K. Lykopoulos, J.R. Diaz, and J. Kleijnen Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive (HR+) and HER2+ advanced or metastatic breast cancer (MBC) Curr Med Res Opin 28 2012 1263 1279
191. B.N. Rexer, R. Ghosh, A. Narasanna, M.V. Estrada, A. Chakrabarty, and Y. Song Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 Clin Cancer Res 19 2013 5390 5401
192. F. Puglisi, A.M. Minisini, C. De Angelis, and G. Arpino Overcoming treatment resistance in HER2-positive breast cancer: potential strategies Drugs 72 2012 1175 1193
193. R.M. Hudziak, G.D. Lewis, M. Winget, B.M. Fendly, H.M. Shepard, and A. Ullrich p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor Mol Cell Biol 9 1989 1165 1172 (Pubitemid 19071685)
194. P. Carter, L. Presta, C.M. Gorman, J.B. Ridgway, D. Henner, and W.L. Wong Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 1992 4285 4289
195. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
196. S. Verma, and M.S. Ewer Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol 22 2011 1011 1018
197. J. Baselga, J. Albanell, M.A. Molina, and J. Arribas Mechanism of action of trastuzumab and scientific update Semin Oncol 28 2001 4 11 (Pubitemid 33065104)
198. S. Varchetta, N. Gibelli, B. Oliviero, E. Nardini, R. Gennari, and G. Gatti Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2 Cancer Res 67 2007 11991 11999
199. M.X. Sliwkowski, and I. Mellman Antibody therapeutics in cancer Science 341 2013 1192 1198
200. C.A. Hudis Trastuzumab - mechanism of action and use in clinical practice N Engl J Med 357 2007 39 51 (Pubitemid 47026733)
201. H.M. Shepard, C.M. Brdlik, and H. Schreiber Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family J Clin Invest 118 2008 3574 3581
202. B.N. Rexer, and C.L. Arteaga Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications Crit Rev Oncog 17 2012 1 16
203. M.C. Franklin, K.D. Carey, F.F. Vajdos, D.J. Leahy, A.M. de Vos, and M.X. Sliwkowski Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 5 2004 317 328 (Pubitemid 38482068)
204. J. Baselga, J. Cortés, S.B. Kim, S.A. Im, R. Hegg, and Y.H. Im Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
205. G.M. Blumenthal, N.S. Scher, P. Cortazar, S. Chattopadhyay, S. Tang, and P. Song First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer Clin Cancer Res 19 2013 4911 4916
206. D.B. Agus, R.W. Akita, W.D. Fox, G.D. Lewis, B. Higgins, and P.I. Pisacane Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 2002 127 137 (Pubitemid 41039113)
207. C.W. Adams, D.E. Allison, K. Flagella, L. Presta, J. Clarke, and N. Dybdal Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab Cancer Immunol Immunother 55 2006 717 727
208. G.D. Lewis Phillips, G. Li, D.L. Dugger, L.M. Crocker, K.L. Parsons, and E. Mai Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 2008 9280 9290
209. S. Verma, D. Miles, L. Gianni, I.E. Krop, M. Welslau, and J. Baselga Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 2012 1783 1791 Erratum in: N Engl J Med 2013;368:2442
210. P.M. LoRusso, D. Weiss, E. Guardino, S. Girish, and M.X. Sliwkowski Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer Clin Cancer Res 17 2011 6437 6447
211. S.A. Hurvitz, L. Dirix, J. Kocsis, G.V. Bianchi, J. Lu, and J. Vinholes Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J Clin Oncol 31 2013 1157 1163
212. R. Bose, S.M. Kavuri, A.C. Searleman, W. Shen, D. Shen, and D.C. Koboldt Activating HER2 mutations in HER2 gene amplification negative breast cancer Cancer Discov 3 2013 224 237
213. R. Roskoski Jr. STI-571: an anticancer protein-tyrosine kinase inhibitor Biochem Biophys Res Commun 309 2003 709 717 (Pubitemid 37122587)
214. Y. Miki, J. Swensen, D. Shattuck-Eidens, P.A. Futreal, K. Harshman, and S. Tavtigian A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 1994 66 71 (Pubitemid 24345325)
215. R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal, and J. Mangion Identification of the breast cancer susceptibility gene BRCA2 Nature 378 1995 789 792 Erratum in: Nature 1996;379:749 (Pubitemid 26004412)
216. R. Wooster, and B.L. Weber Breast and ovarian cancer N Engl J Med 348 2003 2339 2347 (Pubitemid 36638109)
217. R. Roy, J. Chun, and S.N. Powell BRCA1 and BRCA2: different roles in a common pathway of genome protection Nat Rev Cancer 12 2011 68 78
218. R.A. Weinberg The biology of cancer 2nd ed. 2014 Garland Science New York 550
219. N.D. Kauff, J.M. Satagopan, M.E. Robson, L. Scheuer, M. Hensley, and C.A. Hudis Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 2002 1609 1615 (Pubitemid 34755668)
220. T.R. Rebbeck, H.T. Lynch, S.L. Neuhausen, S.A. Narod, L. Van't Veer, and J.E. Garber Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 2002 1616 1622 (Pubitemid 34755669)
221. T.R. Rebbeck, N.D. Kauff, and S.M. Domchek Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 2009 80 87
222. S.M. Domchek, T.M. Friebel, C.F. Singer, D.G. Evans, H.T. Lynch, and C. Isaacs Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality J Am Med Assoc 304 2010 967 975
223. S.A. Narod BRCA mutations in the management of breast cancer: the state of the art Nat Rev Clin Oncol 7 2010 702 707
224. K.A. Phillips, R.L. Milne, M.A. Rookus, M.B. Daly, A.C. Antoniou, and S. Peock Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers J Clin Oncol 31 2013 3091 3099
225. W.D. Foulkes, K. Metcalfe, P. Sun, W.M. Hanna, H.T. Lynch, and P. Ghadirian Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type Clin Cancer Res 10 2004 2029 2034 (Pubitemid 38375563)
226. J. Lee, and S.H. Ou Towards the goal of personalized medicine in gastric cancer - time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification Discov Med 15 2013 333 341
227. E. Wöll, A. Devries, W. Eisterer, M. Hejna, F. Keil, and H. Stein Chemotherapy in gastric cancer Anticancer Res 28 2B 2008 1213 1219 (Pubitemid 351605984)
228. Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, and A. Sawaki Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
229. S. Li, K.R. Schmitz, P.D. Jeffrey, J.J. Wiltzius, P. Kussie, and K.M. Ferguson Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 2005 301 311 (Pubitemid 40544648)
230. G.N. Gill, T. Kawamoto, C. Cochet, A. Le, J.D. Sato, and H. Masui Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity J Biol Chem 259 1984 7755 7760 (Pubitemid 14081190)
231. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 1995 1311 1318
232. Z. Fan, Y. Lu, X. Wu, and J. Mendelsohn Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells J Biol Chem 269 1994 27595 27602 (Pubitemid 24346592)
233. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr., M.N. Needle, J. Kopit, and R.J. Mayer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208 (Pubitemid 41079832)
234. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, and A. Santoro Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
235. K.Y. Chung, J. Shia, N.E. Kemeny, M. Shah, G.K. Schwartz, and A. Tse Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 2005 1803 1810 (Pubitemid 46211358)
236. M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-Bianchi, and F. Di Nicolantonio Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 2005 279 286 (Pubitemid 40590264)
237. E. Van Cutsem, C.H. Köhne, E. Hitre, J. Zaluski, C.R. Chang Chien, and A. Makhson Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
238. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang, and C.G. Davis Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy Crit Rev Oncol Hematol 38 2001 17 23 (Pubitemid 32194591)
239. R.M. Giusti, K.A. Shastri, M.H. Cohen, P. Keegan, and R. Pazdur FDA drug approval summary: panitumumab (Vectibix) Oncologist 12 2007 577 583 (Pubitemid 350012121)
240. C.H. Köhne, R. Hofheinz, L. Mineur, H. Letocha, R. Greil, and J. Thaler First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer J Cancer Res Clin Oncol 138 2012 65 72
241. J.Y. Douillard, K.S. Oliner, S. Siena, J. Tabernero, R. Burkes, and M. Barugel Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
242. A. Grothey, E. Van Cutsem, A. Sobrero, S. Siena, A. Falcone, and M. Ychou Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
243. S.M. Wilhelm, J. Dumas, L. Adnane, M. Lynch, C.A. Carter, and G. Schütz Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 129 2011 245 255
244. L. Festino, A. Fabozzi, A. Manzo, V. Gambardella, E. Martinelli, and T. Troiani Critical appraisal of the use of regorafenib in the management of colorectal cancer Cancer Manage Res 5 2013 49 55
245. R. Roskoski Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression Crit Rev Oncol Hematol 62 2007 179 213 (Pubitemid 46679285)
246. R. Roskoski Jr. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor Biochem Biophys Res Commun 338 2005 1307 1315 (Pubitemid 41608395)
247. B.S. Jaiswal, N.M. Kljavin, E.W. Stawiski, E. Chan, C. Parikh, and S. Durinck Oncogenic ERBB3 mutations in human cancers Cancer Cell 23 2013 603 617
248. No authors listed Cancer Biol Ther 5 2006 340 342
249. M.H. Cohen, H. Chen, S. Shord, C. Fuchs, K. He, and H. Zhao Approval summary: cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer Oncologist 18 2013 460 466
250. V. Vaccaro, D. Melisi, E. Bria, F. Cuppone, L. Ciuffreda, and M.S. Pino Emerging pathways and future targets for the molecular therapy of pancreatic cancer Expert Opin Ther Targets 15 2011 1183 1196
251. S. Gillen, T. Schuster, C. Meyer Zum Büschenfelde, H. Friess, and J. Kleeff Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages PLoS Med 7 2010 e1000267
252. A. Tamburrino, G. Piro, C. Carbone, G. Tortora, and D. Melisi Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy Front Pharmacol 4 2013 56
253. F. Giuliani, M. Di Maio, G. Colucci, and F. Perrone Conventional chemotherapy of advanced pancreatic cancer Curr Drug Targets 13 2012 795 801
254. H.A. Burris 3rd, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, and M.R. Modiano Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413 (Pubitemid 27251144)
255. T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, and Y. Bécouarn FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
256. D. Páez, M.J. Labonte, and H.J. Lenz Pancreatic cancer: medical management (novel chemotherapeutics) Gastroenterol Clin North Am 41 2012 189 209
257. S. Ueda, S. Ogata, H. Tsuda, N. Kawarabayashi, M. Kimura, and Y. Sugiura The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma Pancreas 29 2004 e1 e8
258. S.S. Ng, M.S. Tsao, T. Nicklee, and D.W. Hedley Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma Mol Cancer Ther 1 2002 777 783
259. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, and S. Gallinger Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966 (Pubitemid 46972777)
260. E. Van Cutsem, W.L. Vervenne, J. Bennouna, Y. Humblet, S. Gill, and J.L. Van Laethem Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer J Clin Oncol 27 2009 2231 2237
261. C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, and M. Perucho Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes Cell 53 1988 549 554
262. V.T. Smit, A.J. Boot, A.M. Smits, G.J. Fleuren, C.J. Cornelisse, and J.L. Bos KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas Nucleic Acids Res 16 1988 7773 7782
263. T.A. Dolecek, J.M. Propp, N.E. Stroup, and C. Kruchko CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009 Neuro-oncol 14 2012 1 49 Erratum in: Neuro-Oncol 2013;15:646-7
264. F.G. Kamar, and J.B. Posner Brain metastases Semin Neurol 30 2010 217 235
265. J.J. Vredenburgh, A. Desjardins, J.E. Herndon 2nd, J. Marcello, D.A. Reardon, and J.A. Quinn Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729 (Pubitemid 350086473)
266. M. Spasic, F. Chow, C. Tu, D.T. Nagasawa, and I. Yang Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme Neurosurg Clin N Am 23 2012 417 427
267. K.J. Hatanpaa, S. Burma, D. Zhao, and A.A. Habib Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance Neoplasia 12 2010 675 684
268. A.J. Ekstrand, C.D. James, W.K. Cavenee, B. Seliger, R.F. Pettersson, and V.P. Collins Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo Cancer Res 51 1991 2164 2172
269. A.J. Wong, J.M. Ruppert, S.H. Bigner, C.H. Grzeschik, P.A. Humphrey, and D.S. Bigner Structural alterations of the epidermal growth factor receptor gene in human gliomas Proc Natl Acad Sci USA 89 1992 2965 2969
270. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 46 2001 3 26 (Pubitemid 33653411)
271. D.W. Rusnak, K. Lackey, K. Affleck, E.R. Wood, K.J. Alligood, and N. Rhodes The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol Cancer Ther 1 2001 85 94
272. J.A. Arnott, and S.L. Planey The influence of lipophilicity in drug discovery and design Expert Opin Drug Discov 86 10 2012 3 75
273. G.F. Smith Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design Prog Med Chem 48 2009 1 29
274. N.A. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem Res Toxicol 24 2011 1420 1456
275. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat Rev Drug Discov 6 2007 881 890 (Pubitemid 350042396)
276. S.D. Bembenek, B.A. Tounge, and C.H. Reynolds Ligand efficiency and fragment-based drug discovery Drug Discovery Today 14 2009 278 283
277. A. Gilman The initial clinical trial of nitrogen mustard Am J Surg 105 1963 574 578
278. K. He, K.R. Iyer, R.N. Hayes, M.W. Sinz, T.F. Woolf, and P.F. Hollenberg Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice Chem Res Toxicol 11 1998 252 259 (Pubitemid 28194348)
279. I.F. Sevrioukova, and T.L. Poulos Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems Dalton Trans 42 2013 3116 3126
280. M. Kato Intestinal first-pass metabolism of CYP3A4 substrates Drug Metab Pharmacokinet 23 2008 87 94
281. M.F. Paine, W.W. Widmer, H.L. Hart, S.N. Pusek, K.L. Beavers, and A.B. Criss A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction Am J Clin Nutr 83 2006 1097 1105 Erratum in: Am J Clin Nutr 2006;84:264 (Pubitemid 44713110)
282. J.J. Lilja, M. Neuvonen, and P.J. Neuvonen Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin Br J Clin Pharmacol 58 2004 56 60 (Pubitemid 38901467)
283. Y.T. Ma, M.H. Cullen, and S.A. Hussain Biology of germ cell tumors Hematol Oncol Clin North Am 25 2011 457 471
284. S.B. Saxman, D. Finch, R. Gonin, and L.H. Einhorn Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University experience J Clin Oncol 16 1998 702 706 (Pubitemid 28135618)
285. R. Küppers, A. Engert, and M.L. Hansmann Hodgkin lymphoma J Clin Invest 122 2012 3439 3447
286. R. Advani Optimal therapy of advanced Hodgkin lymphoma Hematology (Am Soc Hematol Educ Program) 2011 2011 310 316
287. N.S. Horowitz, D.P. Goldstein, and R.S. Berkowitz Management of gestational trophoblastic neoplasia Semin Oncol 36 2009 181 189
288. D.P. Goldstein, and R.S. Berkowitz Current management of gestational trophoblastic neoplasia Hematol Oncol Clin North Am 26 2012 111 131
289. L. Deng, J. Zhang, T. Wu, and T.A. Lawrie Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour Cochrane Database Syst Rev 1 2013 CD005196
290. E. Winer, J. Gralow, L. Diller, B. Karlan, P. Loehrer, and L. Pierce Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology J Clin Oncol 27 2009 812 826 Erratum in: J Clin Oncol 2009;27:3070-1
291. J.S. Khorashad, and M.W. Deininger Selection of therapy: rational decisions based on molecular events Hematol Oncol Clin North Am 25 2011 1009 1023
292. H. Kantarjian, and S. O'Brien The chronic leukemias L. Goldman, A. Schafer, W. Arend, Cecil medicine 24th ed. 2012 Elsevier Saunders Philadelphia 1209 1218
293. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
294. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, and J. Sosman Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
295. M. Colombo, F. Corsi, D. Foschi, E. Mazzantini, S. Mazzucchelli, and C. Morasso HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: outlook and recent implications in nanomedical approaches Pharmacol Res 62 2010 150 165
296. Z.A. Knight, H. Lin, and K.M. Shokat Targeting the cancer kinome through polypharmacology Nat Rev Cancer 10 2010 130 137
297. E.A. Kuczynski, D.J. Sargent, A. Grothey, and R.S. Kerbel Drug rechallenge and treatment beyond progression-implications for drug resistance Nat Rev Clin Oncol 10 2013 571 587
298. T. Kurata, K. Tamura, H. Kaneda, T. Nogami, H. Uejima, and Asai Go Go Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance Ann Oncol 15 2004 173 174
299. S. Yano, E. Nakataki, S. Ohtsuka, M. Inayama, H. Tomimoto, and N. Edakuni Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases Oncol Res 15 2005 107 111 (Pubitemid 40825922)
300. A.S. Wong, K.Y. Seto, T.M. Chin, and R.A. Soo Lung cancer response to gefitinib, then erlotinib, then gefitinib again J Thorac Oncol 3 2008 1077 1078
301. B. Escudier, C. Szczylik, C. Porta, and M. Gore Treatment selection in metastatic renal cell carcinoma: expert consensus Nat Rev Clin Oncol 9 2012 327 337
302. J.E. Chaft, G.R. Oxnard, C.S. Sima, M.G. Kris, V.A. Miller, and G.J. Riely Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design Clin Cancer Res 17 2011 6298 6303
303. J.F. Gainor, and A.T. Shaw Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer J Clin Oncol 31 2013 3987 3996
304. D. Santini, B. Vincenzi, R. Addeo, C. Garufi, G. Masi, and M. Scartozzi Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol 23 2012 2313 2318
305. H.M. Kantarjian, T. Fojo, M. Mathisen, and L.A. Zwelling Cancer drugs in the United States: justum pretium - the just price J Clin Oncol 31 2013 3600 3604